🇺🇸 PIPERACETAZINE in United States

FDA authorised PIPERACETAZINE on 3 February 1969 · 12 US adverse-event reports

Marketing authorisations

FDA — authorised 3 February 1969

  • Application: NDA013615
  • Marketing authorisation holder: DOW PHARM
  • Local brand name: QUIDE
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Rebound Effect — 2 reports (16.67%)
  2. Uveitis — 2 reports (16.67%)
  3. Acute Kidney Injury — 1 report (8.33%)
  4. Bone Marrow Failure — 1 report (8.33%)
  5. Cerebrovascular Accident — 1 report (8.33%)
  6. Clostridium Test Positive — 1 report (8.33%)
  7. Coronary Artery Disease — 1 report (8.33%)
  8. Dehydration — 1 report (8.33%)
  9. Drug Ineffective — 1 report (8.33%)
  10. Haemodialysis — 1 report (8.33%)

Source database →

PIPERACETAZINE in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is PIPERACETAZINE approved in United States?

Yes. FDA authorised it on 3 February 1969; FDA has authorised it.

Who is the marketing authorisation holder for PIPERACETAZINE in United States?

DOW PHARM holds the US marketing authorisation.